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background: Magnesium deficiency has been associated with development of various arrhythmias. Correcting the deficiency with oral magnesium 
L-lactate may provide antiarrhythmic efficacy in patients with an implantable cardioverter defibrillator (ICD).
methods: This prospective, double-blind, placebo-controlled trial randomized 70 patients with an ICD to receive oral magnesium L-lactate 
3 tablets twice daily (504mg elemental magnesium daily) or matching placebo for 12 months. Patients were seen at baseline, 3, 6, 9, and 12 
months after randomization. The primary endpoint was the cumulative occurrence of ICD therapies [either shock or anti-tachycardia pacing (ATP)] 
between the groups. Secondary outcomes included cumulative occurrence of ICD shocks and ATP separately. Serum and intracellular magnesium 
concentrations as well as various noninvasive hemodynamic parameters (including cardiac output and systemic vascular resistance) were also 
measured.
results: Baseline serum (2.2 ± 0.2 mg/dL) and intracellular (32.4 ± 1.6 mEq/IU) magnesium levels were below normal in our population. Among 
the 70 randomized patients with a mean [± standard deviation (SD)] follow-up of 6.4 ± 4.1 months, the primary endpoint occurred in 10 patients in 
the placebo group and 8 in the magnesium group (unadjusted hazard ratio 0.84 for magnesium, 95% confidence interval 0.33 to 2.12; p=0.706). 
No significant difference in the occurrence of ICD shocks (p=0.779) or ATP (p=0.870) were seen between groups. No difference in either serum 
or intracellular magnesium concentrations were seen a 3 and 6 months (p>0.498 for all) were seen. Hemodynamic parameters were also similar 
between groups.
conclusion: Use of oral magnesium L-lactate did not significantly impact occurrence of ICD therapies at the doses evaluated, although the overall 
event rate was low.
